Answers are grounded in this paper and cite their sources.
We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.
No takes yet. Share an insight, caveat, or question.
Kolstad et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: